cyrilzakka/clinical-trials huggingface dataset:
Effect of Inhibitory Kinesio-tape of the Upper Trapezius on Lower Trapezius Muscle Excitation

Shoulder pain increases excitation (or activity) of the upper trapezius (UT) and reduces excitation in lower trapezius (LT). Despite inconclusive evidence, kinesio-tape (KT) is often used to modify muscular excitation within the UT and/or LT to help correct alterations in scapular position and motion associated with shoulder pain/injury. The objectives of the current study were to determine if: 1) inhibitory KT to the UT acutely increases muscle excitation (whole-muscle and spatial distribution) within the LT in healthy individuals; and 2) if loading the limb alters the magnitude of change in muscle excitation of the LT. We hypothesize that: 1) inhibitory KT application to the UT will immediately increase whole-muscle LT excitation, and result in an inferior shift in the distribution of excitation within the LT compared to no tape and sham-KT tape conditions; and 2) the magnitude of immediate increase in LT excitation with KT would be greater in the loaded condition. A repeated-measures, crossover design was used to determine the impact of KT applied to UT and load on muscle excitation of the LT. Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. A baseline trial (no KT; N-KT) was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition. The order of the E-KT and S-KT conditions were randomized and the order was counterbalanced. Testing for each tape condition lasted approximately 10-minutes for a total of 45-minutes per participant including screening, EMG set-up and clean-up. KT was applied to the UT and muscle excitation (EMG amplitude) was measured in the LT using one single 32-grid high-density surface electromyography (HD-sEMG) electrode during a repeated arm elevation task.


Eligibility Criteria:
Inclusion Criteria:

* right-handed individuals
* no current shoulder pain or pathology in the shoulder, neck, back.

Exclusion Criteria:

* recent history (\<6 months) of injury or orthopedic disorder of the shoulder, upper back or neck (e.g. rotator cuff tears, disc pathologies, etc.)
* neurological or musculoskeletal disorder (e.g. epilepsy, multiple sclerosis, etc.)
* current pain in the shoulder, upper back or neck
* previous allergies or skin irritation to adhesives.
The Efficacy of Hyaluronic Acid and Honey in Healing of Multiple Extraction Sockets of Primary Teeth Compared to Saline

This study aims to evaluate the effect of hyaluronic acid and honey compared to saline in healing of multiple extraction sockets of primary teeth in a group of children aging from Two to Seven years old.

A dental extraction is one of the most unpleasant experiences in children, especially for those who have undergone traumatic experiences, and this is likely to reduce future visits to the dental clinic if the treatment is not managed properly.

Alveolar osteitis is one of the most common complications following dental extraction. It is considered one of the most studied complications in dentistry, and many risk factors contribute to its occurrence including being a female, young age, tobacco use, difficult or traumatic extractions, pre-existing infection, and use of vasoconstrictor in local anesthesia. Alveolar osteitis occurs during the first three days following the day of extraction, so that the socket is devoid of the blood clot, resulting in the exposure of the bare alveolar bone.

Many medicines were and are still used in treating wounds, but they are somewhat expensive.

Eligibility Criteria:
Inclusion Criteria:

* • Age: from Two to Seven years old age.

  * Both genders.
  * Children with badly decayed multiple primary teeth beyond repair.
  * Treated under general anesthesia.

Exclusion Criteria:

* • History of systemic disease.

  * Allergy to honey.
  * Repeatedly used honey during the previous 6 month period.
The Effects of Intradialytic Exercise in Hemodiafiltration Patients

Low physical activity is associated with in hemodialysis and hemodiafiltration (HDF) patients. Previous studies showed the benefits of intradialytic exercise for improvement of physical fitness and hemodialysis adequacy. However, the effect of intradialytic exercise on physical activity has not been explored. This current open-labelled randomized controlled trial is conducted in HDF patients to determine the effect of intradialytic exercise program for 6 months on daily physical activity measured by tri-axial accelerometer (wearable device).

The study is an open-labelled randomized controlled trial which compare the changes of daily physical activity measured by tri-axial accelerometer (wearable device) between the HDF patients in intradialytic exercise group and control during the 6-month period. After inclusion in to the study, all of the participants will be evaluated before randomized. The investigators will prescribe the exercise program for each participant in the exercise group. The exercise program use intradialytic cycling which will be gradually increased to at least 30 minutes with moderate intensity. The participants in control group will receive dialysis as usual without intradialytic exercise prescription. The participants will go on the program for at least 6-months period. In each session, any adverse event or side effect will be reported.

Eligibility Criteria:
Inclusion Criteria:

* Dialysis vintage more than 3 months
* Sedentary or light physical activity

Exclusion Criteria:

* recent myocardial infarction (\<12 months)
* recent ischemic stroke (\<12months)
* uncontrolled comorbidities (diabetes/hypertension/heart failure/heart disease/respiratory disease)
* Life expectancy \< 12 months
* active musculoskeletal problem e.g.) rheumatoid arthritis, spondyloarthropathy, osteoarthritis, fracture
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received an Adicet Bio allogeneic γδ CAR T cell product that has been genetically engineered to express the anti-CD20 CAR by transduction with a self-inactivating, replication incompetent gamma retroviral vector. The period of follow-up is 15 years after the administration of the γδ CAR T cell product.

The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to a genetically engineered CAR in Adicet Bio clinical studies. Upon early termination/discontinuation or completion of the parent interventional study, subjects will enroll into this study. Collection of these data will further define the risk-benefit and efficacy profile Adicet allogeneic γδ CAR T cell investigational products.

This is an observational study, and the elements of the study design are per published guidelines for gene therapy medicinal products that utilize integrating viral vectors such as gamma retrovirus and it is important to evaluate any delayed adverse events after infusion with such products.

Eligibility Criteria:
Inclusion Criteria:

* All patients who received any Adicet allogeneic CAR T investigational product and have either completed the core treatment protocol or have discontinued early
* All patients who are willing and able to adhere to the study visit schedule and other protocol requirements.
* Capable of giving signed informed consent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and protocol

Exclusion Criteria:

* There are no specific exclusion criteria for this study
M8891 First in Human in Solid Tumors

The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1.


Eligibility Criteria:
Inclusion Criteria:

* Participants must be refractory to or intolerant of existing cancer therapy(ies) known to provide clinical benefit.
* Histologically confirmed advanced solid tumors with no clear curative treatment options available after at least 1 prior systemic anticancer therapy.
* Tumor accessible for biopsies and agreement to conduct pre-dose and post-dose fresh tumor biopsies.
* Male or female subjects at least 18 years of age
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at Screening
* Histologic or cytologic evidence/proven of metastatic renal cell carcinoma (mRCC) with clear cell component
* Part 2A: Participants should have progressed to 1 or more previous lines of systemic anticancer therapy, excluding treatment with cabozantinib
* Part 2B: Participants should have progressed to 1 or 2 previous lines of systemic anticancer therapy, excluding treatment with cabozantinib. Participants should have failed to only 1 previous TKI for metastatic disease. Adjuvant therapy with sunitinib will be considered as 1 line of therapy for metastatic disease in the case that disease progression occurs during or within 3 months of the completion of the treatment.
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* ECOG PS \>= 2
* Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years of study start.
* Severe bone marrow, renal or liver impairment.
* Tumor in contact with, invading or encasing major blood vessels or radiographic evidence of significant cavitary pulmonary lesions
* Uncontrolled hypertension defined as sustained Blood Pressure (BP) \> 150 millimeters of mercury (mm Hg) systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment
* Participant is pregnant or breastfeeding
* Part 2A and 2B: Previous use of cabozantinib or a MetAP2 inhibitor, tumor in contact with invading or encasing major blood vessels or radiographic evidence of significant cavitary pulmonary lesions
* Other protocol defined exclusion criteria could apply
Anxiety, Mood, and Health Behaviors in Young Adults

This is a randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds.

This is a 2-arm randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds. Participants will be 18-35 year-olds with high anxiety sensitivity randomized to 1)Exercise Exposure Intervention or 2)Assessment Only Control Condition. Participants in both groups will be followed for 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Ages 18-35
* Elevated anxiety sensitivity (ASI-3 score \>=23)
* Able to safely participate in moderate-intensity physical activity as assessed by the Physical Activity Readiness Questionnaire (PAR-Q), which will be administered during screening

Exclusion Criteria:

* Current aerobic exercise routine - Measured using the L-CAT with an established cut point of \>2 (assessed at screening)
* Receiving ongoing psychotherapy or counseling (Self-report at screening)
* Recent change in psychotropic medication for anxiety (Self-report at screening)
* Psychiatric hospitalization in past 6 months (Self-report at screening)
* Current pregnancy (Self-report at screening)
Effectiveness of High Protein Diets in Promoting Weight Loss in Overweight and Obese Subjects.

Several studies have reported greater weight loss when following high meat-protein diets but limited studies have studied high plant-based protein diets. Thus we aim to investigate the effect of high protein diets in weight management and also to investigate the superior protein source in achieving this effect. In addition, we aim to develop dietary intervention strategies that are realistic and sustainable.

Participants will be randomised to either high-protein diets (30% of energy) from animal or plant sources or standard protein diet (15% of energy) weight loss diet for 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Overweight or obese
* Age 18 and above
* Both males and females
* Live in Illawarra Area of Australia

Exclusion Criteria:

* Regular medication
* Smoker
* Food allergies
* Presence of disease which may alter metabolic rate
Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3

The purpose of this study is to evaluate safety and efficacy of anti-cholinesterase therapy on the motor function in SMA type 3 patients with impaired neuromuscular junction (NMJ).

Spinal muscular atrophy (SMA) is the second neuromuscular disease meet in children. SMA is a genetically transmitted disease inducing muscular weakness predominating on shoulders and hips. Currently, there is no effective therapy to slow the progression of the disease. SMA is due to a neuron motor attempt of the spinal cord and recently it has been demonstrated a neuromuscular junction (NMJ) involvement, according to recent studies.

EMOTAS study aim to understand if NMJ abnormalities could have an impact on motor performance and fatigue in SMA type 3 ambulatory patients by electromyogram and to improve by non-invasive therapy quality of life of patients.

Eligibility Criteria:
Inclusion Criteria:

* Spinal muscular atrophy type 3, genetically confirmed

  * Age higher than 6 years old
  * Ambulatory patient
  * Informed consent signed
  * More than 100 meters of walking at 6-minute walk test at screening
  * Value at screening and baseline in a range of 20% of the highest value at 6-minute walk test

Exclusion Criteria:

* Patient who had surgical intervention or suffer from a recent traumatism (less than 6 months)

  * Associated pathology such as endocrinopathy, infectious disease, allergy, myopathy, chronic or acute inflammatory pathology, during 3 weeks preceding the inclusion.
  * Other therapeutics than food supplements or those frequently prescribed in spinal muscular atrophy or its complications
  * Non tolerance of electromyography
  * Limited collaboration due to trouble in information comprehension
  * Pathology inducing contra-indication for pyridostigmine treatment (allergy at molecule, asthma, Parkinson disease, mechanic obstruction of urinary or digestive tracts)
Occupational Self Analysis in People with a Serious Mental Illness.

In this study we test the efectiveness of an intervention called 'Occupational sefl-analysys' where particiapants are taught to analyze what activities they do and why do they choose those activities. Also they are encouage to reflect about those occupations that don't do but will like to. In case they want to , they can make changes in their occupational routines. After he program we assessed the improvements in life satisfaction, participation in meaningful activities, perception of balance and occupational satisfaction,

The appearance of a mental disorder forces the person to modify their occupational choices and participation, due, among other aspects, to the continuous presence of symptoms and relapses. 'Occupational self-analysis' programs are based on increasing occupational awareness to promote changes in meaningful occupational participation. The objective of this study was to test the effectiveness of the 'Occupational self-analysis' program in people with Serious Mental Disorder specially on life satisfaction, participation in meaningful activities, perception of balance and occupational satisfaction, compared to the standard intervention received in a Therapeutic Community of Mental Health.

The program was implemented for 4 months, twice a week, while the control group received the standard treatment.

Ten people participated in the 'Occupational self-analysis' program. Results show that participants improved their perception of occupational balance and occupational satisfaction, as well as increasing their participation in meaningful activities.

Eligibility Criteria:
Inclusion Criteria:

* Having a serious mental illness
* Living in the Therapeutic Community or attend the device's day program.

Exclusion Criteria:

* Havin Acute psychopathology
* Diagnosis of cognitive impairment
* Dependence or abuse of toxic substances
Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts

The goal of this study is to explore cognitive burden perceptions among physicians in relation to case report writing. Furthermore, this study evaluates the use of artificial intelligence (AI) assistance as a tool to reduce cognitive burden among providers preparing and submitting case reports. If an AI-tool is helpful in this setting, it may potentially help increase reporting of rare medical events and thereby improve the evidence base for care of these patient populations. This study will occur at a single time point which is expected to last approximately 2 hours. This session will include reviewing two rare tumor cases and then writing a clinical vignette with and without AI assistance.


Eligibility Criteria:
Inclusion Criteria:

1. The subject is a physician, medical student, or postdoctoral student.

Exclusion Criteria:
A Trial of Patients With a Charles Bonnet Syndrome

Charles Bonnet Syndrome (CBS) is defined by the occurence of visual hallucinations (VH) in the absence of any mental disorder. Elderly patients with reduced visual acuity due to ophthalmic diseases are most affected. Conditions are often associated with the syndrome of age-related macular degeneration, cataract or glaucoma. Existing data on the syndrome's prevalence in Europe reveal diverse results. Aim of this study was to assess the prevalence of CBS in patients with low visual acuity and to evaluate, if an additional therapeutic interview with and treatment by a psychiatrist is beneficial.

Patients with a visual acuity of 0.5 LogMAR or less in the better eye were screened for CBS. Instruments used were an interview asking for details of the hallucinations, a mental test and a scale concerning quality of life. Patients with CBS were randomized by minimization in two groups: in group 1, a patient-doctor interview by an ophthalmologist was performed and in group 2 an interview and if needed, a therapy by a psychiatrist. At the 3-months follow up, the psychological strain of patients was recorded again.

Eligibility Criteria:
Inclusion Criteria:

* written informed consent
* visual acuity of 0.5 LogMAR or less at both eyes
* 55 years or older

Patients with CBS:

* have no mental pathologies such as dementia, psychosis or any other neurological diseases
* have a normal cognitive state
* are not able to control the VH
* know that the VH are not real
* are usually older
* have significantly reduced visual acuity due to an bilateral eye pathology

VH associated with CBS:

* disappear when the eyes are closed
* are repetitive
* are complex (eg. objects, geometrical patterns, faces, shapes, figures, scenes, animals or plants)

Exclusion Criteria:

* dopamine agonist medication
* temporal lobe epilepsy
* moderate to severe Alzheimer's dementia
* present chronic alcohol-/drug abuse
* bad cognitive state

There are no:

* auditory or olfactory hallucinations
* other abnormalities like delusions
The Effects of Virtual Reality/ Augmented Reality Usage on Oral Care Knowledge in Nursing Students

The aim of this study was to investigate the effects of virtual reality usage on oral care knowledge in nursing students. The participants were randomly assigned to virtual-reality experimental and control groups. The students in experimental group received a 30 minutes virtual reality (VR) training for elderly oral health care at the second week and the fourth week after the first time survey. All students self-administrated questionnaire three times at first date of consent form signed, immediately after each of the intervention for period of two weeks. Linear regression in generalized estimating equations (GEE) compare the differences between both groups.

A total of 50 first-year to third-year undergraduate nursing students were included from the Department of Nursing, Kaohsiung Medical University, Taiwan. The students were randomly assigned divided at random into two groups, control (n = 25) and experimental (n = 25).

Eligibility Criteria:
Inclusion Criteria:

1. undergraduate freshman, sophomore, and junior nursing students
2. those volunteered to participate in this study

Exclusion Criteria:

1. students with known negative effects of using VR devices, such as nausea, vomiting, etc.
2. those under 20 years of age who had not obtained the consent of a legal representative to participate in this study.
Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

Researchers are assessing the effects of weight loss medication vs a placebo among participants provided with a wearable activity tracker, digital wellness devices and lifestyle recommendations.


Eligibility Criteria:
Inclusion Criteria

* Adults with obesity (BMI \>30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.
* Age: 18-75 years.
* Gender: Men or women. Women of childbearing potential will have negative pregnancy tests within 48 hours of enrollment.
* Women of childbearing potential must agree to use a method of effective contraception during study participation.
* Subject must have an Apple iPhone 6s or later with iOS 13 or later and be willing to download the VitalCare (VitalTech Affiliates LLC) application from the Apple App Store.
* Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures

Exclusion Criteria

* History of Abdominal bariatric surgery
* Weight is greater than 450 lbs (204 kg)
* Recent use (within the last three months) of any antiobesity medication
* Recent weight change (gain or loss weight greater than 3% TBW in the last 3 months)
* Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.
* Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score \>11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
* Hypersensitivity or contraindication to the study medication.
* Participant unable or unwilling to follow protocol including use of the wearable activity tracker, digital wellness devices, VitalCare application, or unwilling to sign consent.
* Principal Investigator discretion